Portray, a precision medicine-based tech biotechnology company, announced on the 2nd that it has secured 14.5 billion won in Series B funding. Major venture capital firms including Stick Ventures, BNH Investment, Kakao Ventures, Envisioning Partners, Bon Angels Venture Partners, Pearl Abyss Capital, and CKD Venture Investment participated in the round.
Portray has built a space-transcriptome-based cancer data platform and combined it with AI-based analysis technologies to enhance the efficiency of new drug development. Recently, the company has been developing an analysis platform that precisely interprets patient tissue data based on spatial biology, a field attracting attention in the next-generation life sciences.
The platform being developed by Portray aims to identify new drug target candidates more accurately and quickly by integrating gene expression patterns and pathological structures.
Portray was selected as an award winner in the "Golden Ticket" program, hosted by global pharmaceutical company Amgen and the Korea Health Industry Development Institute. It is also participating in the Open Innovation Program with Celltrion and Seoul Biohub. Currently, joint research is underway with Celltrion to identify new drug targets.
The company plans to use this investment to accelerate the advancement of its spatial transcriptome-based patient-derived database, the discovery of new drug targets based on multi-omics analysis, and the expansion of joint research with global pharmaceutical companies. Through these efforts, the company aims to accelerate the practical implementation of AI-based precision medicine and its leap forward as a platform-based global tech biotechnology company.
“This investment is a testament to the potential of AI-based tech-bio companies,” said Lee Dae-seung, CEO of Portray. “We will continue to expand the depth and resolution of space-based cancer data to enable precise target discovery and personalized treatment.”
You must be logged in to post a comment.